F. Mefti

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Chrystelle Brignone, Maya Gutierrez, F. Mefti et al. · Journal of Translational Medicine · 2010 · 253 citations · Full text

Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis

Claire Bonneau, Gilles Paintaud, Olivier Trédan et al. · European Journal of Cancer · 2018 · 95 citations

Breast Oncology, Intrathecal Administration, Breast Cancer +4

Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial

Michael Brundage, M. Gropp, F. Mefti et al. · Annals of Oncology · 2012 · 45 citations

Health-related Quality, Medicine, Cancer Management +6

Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial

Claire Falandry, Étienne Brain, Marc Bonnefoy et al. · European Journal of Cancer · 2013 · 30 citations

Final Results, Breast Oncology, Oncology +11

First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

Djelila Allouache, Sulochana R. Gawande, M. Tubiana-Hulin et al. · BMC Cancer · 2005 · 27 citations · Full text